Item 7.01 Regulation FD Disclosure.

On January 19, 2022, the Company announced it has launched B2B sales of the rare cannabinoid cannabicitran (CBT) into the health and wellness sector and that CBT is the first of several new product launches planned for the first half of 2022.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:





Exhibit No.   Description
99.1            News release, dated January 19, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document and included as Exhibit 101)




                                       1

© Edgar Online, source Glimpses